All > Surgery

Chemoradiation + EBRT Boost for Stage II Rectal Cancer

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Stage II Rectal CancerChemoradiation + EBRT Boost - Radiation
Eligibility
18 - 80
All Sexes
What conditions do you have?
Select

Study Summary

This trial is studying two different types of radiation therapy for rectal cancer.

Eligible Conditions
  • Stage II Rectal Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Radiation Therapy
1
Trifluridine and Tipiracil Hydrochloride
1
Ultrafractionated radiotherapy for rectal cancer

Study Objectives

2 Primary · 4 Secondary · Reporting Duration: 5 years post treatment

2 years post treatment
Local Recurrence
Rectum preservation in treated patients
TME-free survival
5 years post treatment
Disease-free survival
Overall Quality of life
Overall survival

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
Radiation Therapy
1
Trifluridine and Tipiracil Hydrochloride
1
Ultrafractionated radiotherapy for rectal cancer

Trial Design

2 Treatment Groups

Chemoradiation + EBRT Boost
1 of 2
Chemoradiation + HDRBT Boost
1 of 2

Experimental Treatment

145 Total Participants · 2 Treatment Groups

Primary Treatment: Chemoradiation + EBRT Boost · No Placebo Group · Phase 2 & 3

Chemoradiation + EBRT BoostExperimental Group · 2 Interventions: Complete responders and Non-complete responders, Chemoradiation + EBRT Boost · Intervention Types: Procedure, Radiation
Chemoradiation + HDRBT BoostExperimental Group · 2 Interventions: Complete responders and Non-complete responders, Chemoradiation + HDRBT Boost · Intervention Types: Procedure, Radiation

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 5 years post treatment

Who is running the clinical trial?

Sir Mortimer B. Davis - Jewish General HospitalLead Sponsor
52 Previous Clinical Trials
18,538 Total Patients Enrolled
Te Vuong, MDPrincipal InvestigatorSir Mortimer Jewish General Hospital
6 Previous Clinical Trials
292 Total Patients Enrolled

Eligibility Criteria

Age 18 - 80 · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a tumor located at less than 10 cm from the anal verge.
You have a rectal cancer staged as N0 by MRI or EUS/TRUS.
You have a tumor less than 5 cm on its largest dimension.
The tumor is less than 5 mm in the mesorectal fat.
The lumen of the colon is accessible for colonoscopy.
Patient should be a suitable candidate for brachytherapy and chemotherapy.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top